Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 6Unknown 2Terminated 2Not yet recruiting 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colonic Neoplasms 4Pancreatic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Colorectal Neoplasms 2Clinical Stage I Gastric Cancer AJCC v8 2Anus Neoplasms 2Tongue Neoplasms 1Sinonasal undifferentiated carcinoma 1Salivary Gland Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Adenocarcinoma 1PRETEXT I Hepatoblastoma 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Klatskin Tumor 1Keratosis, Actinic 1Hypopharyngeal Neoplasms 1Hepatoblastoma 1HIV Infections 1Gallbladder Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Epstein-Barr Virus Infections 1DNA Repair-Deficiency Disorders 1Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

Bevacizumab 30pembrolizumab 29Oxaliplatin 28Leucovorin 25Fluorouracil 24Irinotecan 22Cetuximab 22Capecitabine 19Nivolumab 15Specimen Handling 12atezolizumab 11Panitumumab 11Colonoscopy 9Carboplatin 9regorafenib 8Biopsy 8trifluridine tipiracil drug combination 7Trifluridine 7Paclitaxel 7Aspirin 7balstilimab 6Standard of Care 6Cisplatin 6tislelizumab 5encorafenib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunoglobulin G 5Folfox protocol 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Neoplasms × dehydroftorafur × Clear all
NCT02997228 2026-06-03

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
120 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

City of Hope Medical Center

Phase 1/2 Active not recruiting
20 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡